Press Release Mar 18 2026
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Mankind Pharma Ltd. has announced the acquisition of the Rivotril brand for the Indian market, which includes exclusive rights to manufacture, market, and distribute the product in India. This acquisition reinforces the company's focus on chronic central nervous system therapies and enhances its existing neuro portfolio. The company aims to leverage its distribution network to improve access to Rivotril across healthcare institutions and prescribers in India.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Mankind Pharma
- Press Release Feb 03 2026
- Actimed Therapeutics Announces Important Licensing Agreement with Mankind Pharma
- Press Release Nov 06 2025
- Press Release Jul 31 2025
- Press Release May 21 2025
Later from Mankind Pharma
- Press Release May 19 2026
- Mankind Pharma Ltd. Press Release Jul 30 2026
- Mankind Pharma Ltd. Press Release Aug 20 2026
- Mankind Pharma Limited has informed the Exchange regarding a press release dated October 15, 2026, titled "Press Release titled Mankind Pharma to Acquire Majority Stake in Armed Cell Therapeutics, Marking Strategic Entry into Next-Generation CAR-T Therapies ".
- Mankind Pharma Limited has informed the Exchange regarding a press release dated October 26, 2026, titled "Press Release on Financial Results for Q2 & H1 FY27".
Follow Mankind Pharma into a list and get an email when it puts out news.
Follow Mankind Pharma